HK Stock Market Move | LEADS BIOLABS-B(09887) rose more than 8% and officially entered the Hong Kong stock connect. The first patient has been enrolled in the phase II clinical trial of Vilyx II.

LEADS BIOLABS-B (09887) rose more than 8%, as of press time, up 8.08% to HK$58.05, with a turnover of HK$110 million. On the news front, Viela Bio announced that starting March 9, 2026, the company's shares will be included in the Hang Seng Composite Index and added to the list of eligible stocks for Southbound Trading under the Stock Connect program. The inclusion of shares in the Hang Seng Composite Index and Stock Connect program is a strong recognition of the company's performance and value by the capital market. It is expected to further expand the company's investor base, enhance the trading liquidity of the shares, and optimize the shareholder structure. In addition, on March 6, Viela Bio announced that the Phase II clinical trial of the company's self-developed PD-L1/4-1BB bispecific antibody, VLS003 (LBL-024), in combination with first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) has successfully completed the enrollment of the first patient. VLS003 (LBL-024) is a bispecific antibody targeting PD-L1 and 4-1BB, making it the world's first bispecific targeting co-stimulatory receptor 4-1BB in a single-arm pivotal clinical stage. It is expected to become the first approved drug for the treatment of EP-NEC.